Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that

GlobeNewswireJun 19 08:00 ET

Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Resea

GlobeNewswireJun 18 08:00 ET

H.C. Wainwright Initiates Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Announces Target Price $10

H.C. Wainwright analyst Joseph Pantginis initiates coverage on $Lexicon Pharmaceuticals(LXRX.US)$ with a buy rating, and sets the target price at $10.According to TipRanks data, the analyst has a succ

moomoo NewsJun 17 06:33 ET · Ratings

Express News | HC Wainwright & Co. Initiates Coverage On Lexicon Pharmaceuticals With Buy Rating, Announces Price Target of $10

BenzingaJun 17 06:21 ET

Express News | Lexicon Pharmaceuticals, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

ReutersJun 17 06:07 ET

Express News | Lexicon Pharmaceuticals Presents Findings On The Burdens Of Diabetic Peripheral Neuropathic Pain Among 3 Sponsored Presentations At The 84th Scientific Sessions Of The American Diabetes Association

BenzingaJun 14 08:15 ET